Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025

コンパニオン診断の世界市場予測:製品・サービス別(アッセイ、キット、ソフトウェア・サービス)、技術別(PCR、NGS、ISH、IHC)、疾患別(乳がん、肺がん・胃がん、神経疾患)、エンドユーザー別(製薬会社、CRO)、地域別

◆タイトル:Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025
◆商品コード:MD 5463
◆調査・発行会社:MarketsandMarkets
◆発行日:2020年7月15日
◆ページ数:320
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥519,750見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥698,250見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥855,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

MarketsandMarkets社はコンパニオン診断の世界市場が2020年37億ドルから2025年68億ドルまで、年平均12.9%成長すると見込んでいます。本調査レポートでは、コンパニオン診断の世界市場を詳細に調査・分析し、イントロダクション、調査手法、プレミアムインサイト、市場概要、市場動向、製品・サービス別(アッセイ・キット・試薬、ソフトウェア・サービス)分析、技術別(ポリメラーゼ連鎖反応(PCR)、次世代シーケンシング(NGS)、インサイチュハイブリダイゼーション(ISH)、免疫組織化学(IHC)、その他)分析、疾患別(癌、感染症、心血管疾患、神経疾患、その他)分析、エンドユーザー別(製薬・生物医薬品会社、リファレンス研究所、委託研究組織、その他)分析、地域別分析、競争状況、企業概要、隣接・関連市場などを含めており、ご提供いたします。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・市場動向
・コンパニオン診断の世界市場規模:製品・サービス別(アッセイ・キット・試薬、ソフトウェア・サービス)
・コンパニオン診断の世界市場規模:技術別(ポリメラーゼ連鎖反応(PCR)、次世代シーケンシング(NGS)、インサイチュハイブリダイゼーション(ISH)、免疫組織化学(IHC)、その他)
・コンパニオン診断の世界市場規模:疾患別(癌、感染症、心血管疾患、神経疾患、その他)
・コンパニオン診断の世界市場規模:エンドユーザー別(製薬・生物医薬品会社、リファレンス研究所、委託研究組織、その他)
・コンパニオン診断の世界市場規模:地域別
・競争状況
・企業概要
・隣接・関連市場

“The companion diagnostics market is estimated to grow at a CAGR of 12.9%”
The companion diagnostics market is expected to reach USD 6.8 billion by 2025 from USD 3.7 billion in 2020, at a CAGR of 12.9%. The growth of the companion diagnostics industry is tied primarily to its various advantages, the growing need for targeted therapy, the increasing importance of personalized medicine. Moreover, the increasing global incidence of cancer, ever-increasing application areas of companion diagnostics, rising demand for next-generation sequencing, the growing significance of companion diagnostics in drug development, and the increasing number of clinical trials are expected to present growth opportunities for players in the market. However, the high cost of companion diagnostic tests and the uncertain reimbursement scenario in different regions affect market growth to a certain extent during the forecast period.

“Cancer segment to witness the highest growth during the forecast period”
The cancer segment is estimated to grow at the highest CAGR during the forecast period. This can be attributed primarily to the increasing global incidence of cancer, the growing role of companion diagnostics in personalized medicine treatment for cancer, the rising utility of biomarkers in the diagnosis of cancer, technological advancements in cancer diagnostics at the molecular level, and the availability of funding for cancer research.

“Pharmaceutical & biopharmaceutical companies segment to grow at the highest CAGR in the companion diagnostics market, by end-user”
The major factors driving the demand for pharmaceutical & biopharmaceutical companies in companion diagnostics are growing prominence in drug development and the growing importance of companion diagnostic biomarkers. The increasing demand for personalized medicine as well as the high demand for targeted therapies for various diseases and disorders are also expected to drive the demand and uptake of companion diagnostics among pharmaceutical & biopharmaceutical companies.

“APAC market to witness the highest growth during the forecast period”
Asia Pacific is estimated to be the fastest-growing regional market for companion diagnostics during the forecast period. The high incidence of cancer, growing proteomics & genomics research, increasing research funding, rising investments by pharmaceutical and biotechnology companies, and growing awareness about personalized therapeutics in several APAC countries are some of the major factors driving the growth of this market.

The break-down of primary participants is as mentioned below:
• By Company Type – Tier 1: 40%, Tier 2: 25%, and Tier 3: 35%
• By Designation – C-level: 33%, Director-level: 41%, and Others: 26%
• By Region – North America: 38%, Europe: 32%, Asia Pacific: 23%, Latin America: 5%, and the Middle East & Africa: 2%
The prominent players operating in the global companion diagnostics market are F. Hoffmann-La Roche AG (Switzerland), Agilent Technologies, Inc. (US), QIAGEN N.V. (Germany), Abbott Laboratories, Inc. (US), Almac Group (UK), Danaher Corporation (US), Illumina, Inc. (US), bioMérieux SA (France), Myriad Genetics, Inc., (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), Abnova Corporation (Taiwan), Guardant Health, Inc. (US), Icon Plc (Ireland), and Biogenex Laboratories, Inc. (US)

Research Coverage:
This report analyzes the market for various companion diagnostics and their adoption patterns. It aims at estimating the size and future growth potential of the global companion diagnostics market as well as its segments (by product & service, technology, indication, end-user, and region). The report also includes an in-depth competitive analysis of key market players along with their company profiles, product offerings, and recent developments.

Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or any combination of the below mentioned five strategies for strengthening their market presence.
 Market Penetration: Comprehensive information on the product portfolios offered by the top players in the global companion diagnostics market
 Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and service launches in the global companion diagnostics market
 Market Development: Comprehensive information on the lucrative emerging regions
 Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the global companion diagnostics market
 Competitive Assessment: In-depth assessment of product offered, market shares, growth strategies, and revenue analysis of leading players in the global companion diagnostics market

【レポートの目次】



★調査レポート[コンパニオン診断の世界市場予測:製品・サービス別(アッセイ、キット、ソフトウェア・サービス)、技術別(PCR、NGS、ISH、IHC)、疾患別(乳がん、肺がん・胃がん、神経疾患)、エンドユーザー別(製薬会社、CRO)、地域別] ( Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025 / MD 5463) 販売に関する免責事項
[コンパニオン診断の世界市場予測:製品・サービス別(アッセイ、キット、ソフトウェア・サービス)、技術別(PCR、NGS、ISH、IHC)、疾患別(乳がん、肺がん・胃がん、神経疾患)、エンドユーザー別(製薬会社、CRO)、地域別] ( Companion Diagnostics Market by Product & Service (Assay, Kit, Software & Service), Technology (PCR, NGS, ISH, IHC), Indication (Breast, Lung & Gastric Cancer, Neurological Disease), End-User (Pharma Companies, CRO), Region - Global Forecast to 2025 / MD 5463) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆